BridgeBio Pharma (BBIO) Change in Receivables (2024 - 2026)

BridgeBio Pharma has disclosed Change in Receivables across 3 years of filings, most recently posting $65.8 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at $65.8 million, down 40.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $90.0 million (up 174.82% YoY), and the FY2025 annual result was $134.7 million, up 4434.57% from the prior year.
• Change in Receivables came in at $65.8 million for Q1 2026 at BridgeBio Pharma, up from $22.9 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $233.7 million in Q1 2024 to a low of -$234.8 million in Q2 2024.
• The 3-year median for Change in Receivables is $22.9 million (2025), against an average of $22.6 million.
• Peak annual rise in Change in Receivables reached 21885.71% in 2025, while the deepest fall reached 52.71% in 2025.
• BridgeBio Pharma's Change in Receivables stood at $4.2 million in 2024, then jumped by 440.2% to $22.9 million in 2025, then soared by 186.93% to $65.8 million in 2026.
• The last three Change in Receivables figures came in at $65.8 million (Q1 2026), $22.9 million (Q4 2025), and $39.6 million (Q3 2025), per Business Quant data.